Acquiring Company
Gyre Therapeutics
Acquired Company
Cullgen
San DiegoSan DiegoManufacturingBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaBiotechnologyTherapeuticsDescription
Gyre Therapeutics has entered into an agreement to acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million. This acquisition will create a fully integrated biopharmaceutical company with capabilities in both the U.S. and China. The combined entity will target inflammatory diseases and cancers with its robust pipeline and technology. The transaction is anticipated to close early in the second quarter of 2026.
Quick answer
Gyre Therapeutics is acquiring Cullgen for $300 million, announced March 2, 2026. Gyre Therapeutics is based in San Diego, California, United States.
- How much did Gyre Therapeutics pay for Cullgen?
- The reported deal value is $300 million.
- What does Gyre Therapeutics do?
- Gyre Therapeutics is an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases.
- Where are Gyre Therapeutics and Cullgen based?
- Gyre Therapeutics is based in San Diego, California, United States. Cullgen is based in San Diego, California, United States.
- Who are the decision-makers at Gyre Therapeutics?
- Fundz holds 1 contact at Gyre Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cyclerion to merge with Korsana Biosciences (April 1, 2026)
- Aurinia acquires Kezar Life Sciences for $6.955/share (March 30, 2026)
- Merck to acquire Terns Pharmaceuticals for $6.7B, $6.7B (March 25, 2026)
- Biogen to acquire Apellis Pharmaceuticals for $5.6B, $5.6B (April 1, 2026)
- Eli Lilly to acquire Centessa Pharmaceuticals (March 31, 2026)
- Gilead to acquire Ouro Medicines for $2 billion, $2B (March 23, 2026)
Who to call at Gyre Therapeutics, and when
When Gyre Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Gyre Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gyre Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gyre Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gyre Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Cullgen?
Cullgen was acquired by Gyre Therapeutics, based in San Diego. The deal was reported on March 2, 2026. Gyre Therapeutics is an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases. Gyre Therapeutics is publicly traded (GYRE) and operates in Manufacturing.
When did Gyre Therapeutics acquire Cullgen?
Gyre Therapeutics's acquisition of Cullgen was reported on March 2, 2026. Gyre Therapeutics has entered into an agreement to acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million. This acquisition will create a fully integrated biopharmaceutical company with capabilities in both the U.S. and China. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cullgen do?
Cullgen Inc. is a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.